[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100658858":3},{"organization":4,"outcomesModule":7,"designInfo":29,"detailedDescription":28,"studyPopulation":28,"armGroups":38,"interventions":59,"overallOfficials":68,"centralContacts":72,"locations":78,"responsibleParty":92,"collaborators":28,"id":94,"slug":95,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":28,"eligibilityCriteria":100,"healthyVolunteers":101,"sex":102,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":28,"studyType":108,"phases":109,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":116,"whyStopped":28,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"AbbVie","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":28,"otherOutcomes":28},[9,13,17,19,22,25],{"measure":10,"description":11,"timeFrame":12},"Number of Participants with Adverse Events (AEs)","An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.","Up to approximately 38 days",{"measure":14,"description":15,"timeFrame":16},"Maximum Observed Serum Concentration (Cmax) of ABBV-7828","Cmax of ABBV-7828","Up to approximately 10 days",{"measure":18,"description":18,"timeFrame":16},"Time to Cmax (Tmax) of ABBV-7828",{"measure":20,"description":21,"timeFrame":16},"Terminal Phase Elimination Rate Constant (Beta) of ABBV-7828","Beta of ABBV-7828",{"measure":23,"description":24,"timeFrame":16},"Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-7878","AUCt of ABBV-7878",{"measure":26,"description":27,"timeFrame":16},"AUC From Time 0 to the Time Infinity (AUCinf) of ABBV-7878","AUCinf of ABBV-7878",null,{"allocation":30,"interventionModel":31,"interventionModelDescription":28,"primaryPurpose":32,"observationalModel":28,"timePerspective":28,"maskingInfo":33},"RANDOMIZED","SEQUENTIAL","BASIC_SCIENCE",{"masking":34,"maskingDescription":28,"whoMasked":35},"DOUBLE",[36,37],"PARTICIPANT","INVESTIGATOR",[39,45,51,55],{"label":40,"type":41,"description":42,"interventionNames":43},"Part 1: ABBV-7828","EXPERIMENTAL","Participants will receive single doses of ABBV-7828.",[44],"Drug: ABBV-7828",{"label":46,"type":47,"description":48,"interventionNames":49},"Part 1: Placebo","PLACEBO_COMPARATOR","Participants will receive single doses of placebo.",[50],"Drug: Placebo for ABBV-7828",{"label":52,"type":41,"description":53,"interventionNames":54},"Part 2: ABBV-7828 Sequence 1","Participants will receive ABBV-7828 while in fasting in Period 1 followed by ABBV-7828 after high fat\u002Fhigh calorie meal in Period 2.",[44],{"label":56,"type":41,"description":57,"interventionNames":58},"Part 2: ABBV-7828 Sequence 2","Participants will receive ABBV-7828 after a high-fat\u002Fhigh calorie meal in Period 1 followed by ABBV-7828 in fasting conditions in Period 2.",[44],[60,65],{"type":61,"name":62,"description":63,"armGroupLabels":64,"otherNames":28},"DRUG","ABBV-7828","Oral administration",[40,52,56],{"type":61,"name":66,"description":63,"armGroupLabels":67,"otherNames":28},"Placebo for ABBV-7828",[46],[69],{"name":70,"affiliation":5,"role":71},"ABBVIE INC.","STUDY_DIRECTOR",[73],{"name":74,"role":75,"phone":76,"phoneExt":28,"email":77},"ABBVIE CALL CENTER","CONTACT","844-663-3742","abbvieclinicaltrials@abbvie.com",[79],{"facility":80,"status":28,"city":81,"state":82,"zip":83,"country":84,"countryCode":85,"cosmosGeoPoint":86,"geoPoint":91,"contacts":28},"Acpru \u002FId# 283545","Grayslake","Illinois","60030","United States","US",{"type":87,"coordinates":88},"Point",[89,90],-88.04175,42.34447,{"lat":90,"lon":89},{"type":93,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100658858","phase-1-a-single-ascending-dose-and-food-effect-study-of-abbv-7828-in-healthy-adults-100658858",false,"NCT07856706","A Single Ascending Dose, and Food Effect Study of ABBV-7828 in Healthy Adults","A Phase 1, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-7828, and to Evaluate the Effect of Food on ABBV-7828 Pharmacokinetics in Healthy Adult Subjects","Inclusion Criteria:\n\n* Individuals between 18 to 65 years of age at the time of screening.\n* BMI is \\\u003C= 18.0 to \\>= 32.0 kg\u002Fm2.\n* A condition of general good health, based upon the results of a medical history, physical evaluations, vital signs, laboratory profile and a 12-lead ECG.\n\nExclusion Criteria:\n\n* History of epilepsy, any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic or psychiatric disease or disorder, or any uncontrolled medical illness.\n* Has any clinically significant ECG abnormalities including the following:\n\n  * Evidence of 2nd or 3rd degree atrial ventricular (AV) block at screening visit or upon initial confinement\n  * QT interval corrected for heart rate (QTc) using Fridericia's correction formula (QTcF) \\> 450 msec (males) or \\> 460 msec (females) at screening visit or upon initial confinement.\n* History of any clinically significant sensitivity or allergy to any medication or food.\n* History of or active medical condition(s) or surgical procedure(s) that might affect gastrointestinal motility, pH, or absorption.",true,"ALL","18 Years","65 Years",{"count":106,"type":107},60,"ESTIMATED","INTERVENTIONAL",[110],"PHASE1","This study is to evaluate safety, tolerability, pharmacokinetics and effect of food on ABBV-7828 compared to placebo in healthy adult participants.",[113],"Healthy Subjects",[115,62],"Healthy Adult Subjects","NOT_YET_RECRUITING","2026-09-28",{"date":119,"type":120},"2026-10-05","ACTUAL",{"date":122,"type":107},"2026-09-21",{"date":124,"type":107},"2027-05",{"name":5,"class":6},1]